Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.

Tadej Battelino,Thomas Danne,Steve V Edelman,Pratik Choudhary,Eric Renard,Jukka Westerbacka,Bhaswati Mukherjee,Valerie Pilorget,Mathieu Coudert,Richard M Bergenstal

Diabetes, obesity & metabolism（2023）

引用 3|浏览21

暂无评分

摘要

Using clinically relevant CGM metrics, InRange shows that Gla-300 is non-inferior to IDeg-100 in people with T1D, with comparable hypoglycaemia and safety profiles.

查看译文

关键词

basal insulin,continuous glucose monitoring,glycaemic control,insulin analogues,randomized trial,type 1 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要